{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-048529","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2022-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.080673+00:00","generated_at":"2026-06-27T05:50:15.497601+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cerus Q4 revenue $50.1M (+49% YoY); reiterates FY2022 product revenue guidance $157-164M","bullets":["Q4 product revenue $39.9M (+41% YoY); net loss narrowed to $9.1M ($0.05/sh) from $14.4M.","FY2021 total revenue $159.5M (+40% YoY); product revenue $130.9M (+42% YoY).","FY2022 product revenue guidance reaffirmed at $157-164M, representing 20-25% growth.","Two blood centers obtained BLA approvals for INTERCEPT Fibrinogen Complex (IFC), enabling interstate sales.","Cash, equivalents and short-term investments $129.4M at Dec 31, 2021; net cash used in ops $33.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-048529","json":"https://secwatch.observer/filing/0001193125-22-048529.json","markdown":"https://secwatch.observer/filing/0001193125-22-048529.md","text":"https://secwatch.observer/filing/0001193125-22-048529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000119312522048529/0001193125-22-048529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000119312522048529/d317573d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:50:15.497601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}